The life sciences industry is poised for transformation as AI-native drug discovery approaches reshape complex research and development workflows while maintaining the critical need for “wet” labs, designed for hands-on testing and analysis using physical samples.
In From Code to Clinic: How AI Is (and Isn’t) Rewriting the Life of a Drug, William Blair healthcare analyst Matt Larew evaluates how AI is shaping drug discovery, lab automation, and analytical tools. The report also analyzes funding activity and strategic partnerships to highlight competitive dynamics and targeted opportunities for AI adoption across frontier companies.
For more information on William Blair’s healthcare equity research, contact us or your William Blair representative.